GLP-1 RA
41 articles on GLP-1 RA, researched and written by the Shotlee Editorial Team from primary sources.
Ozempic and Wegovy Use Linked to Thousands of Poison Control Calls
The widespread adoption of Ozempic and Wegovy for weight loss has coincided with a significant rise in calls to poison control centers. This article delves into the research behind this trend, highlighting common mistakes and the importance of proper patient education.
6 min read
Ozempic vs. Jardiance: Better Heart Protection for Diabetics with AFib
A new study compares GLP-1 and SGLT-2 inhibitors in patients with type 2 diabetes and atrial fibrillation, revealing significant differences in heart health outcomes.
7 min read
Wegovy Arrives in Jordan: A New Era for Weight Management
Novo Nordisk has officially launched Wegovy®️ (semaglutide 2.4 mg) in Jordan, marking a significant advancement in the country's approach to tackling the growing challenge of excess weight and its associated health risks.
7 min read
Beyond the Headlines: Unpacking the Real GLP-1 Weight Loss Race
The booming GLP-1 market for weight loss is often simplified by headline prescription numbers. This article delves deeper, examining the complex factors influencing the success of drugs like Wegovy, Zepbound, and Mounjaro, and what they mean for patients and the industry.
8 min read
Beyond Hunger: GLP-1s Reveal New Insights into Compulsive Behaviors
Originally developed for diabetes, GLP-1 medications are now revealing profound insights into the neurobiology of desire, reward, and compulsion, impacting everything from food cravings to addictive tendencies.
8 min read
Semaglutide and Tirzepatide: The Reality of Stopping and Restarting
A groundbreaking analysis of diabetes medication patterns reveals that stopping isn't always permanent. Discover which drugs have the best retention rates and how insurance impacts access.
7 min read
Beyond Weight Loss: GLP-1 Drugs Show Potential to Reduce Crime-Linked Behavior
Groundbreaking research indicates that GLP-1 receptor agonists, widely recognized for their impact on diabetes and weight management, may also play a crucial role in modulating impulsive behaviors that can lead to criminal acts and violence.
6 min read
GLP-1 Therapies: Australia's New Blueprint for Obesity and Heart Health
Australia has released a groundbreaking clinical consensus statement on obesity and cardiovascular disease (CVD), marking a pivotal moment in medical practice. This new guidance places GLP-1 receptor agonists—a class of medications including semaglutide and tirzepatide—at the forefront of treatment strategies, offering clinicians a clear, practical pathway for improving patient outcomes.
6 min read
Beyond Willpower: Understanding Obesity's Metabolic Roots
Obesity is a complex, multi-organ disease, not a failure of willpower. This article delves into its metabolic underpinnings and outlines a practical approach to management, including modern medications and lifestyle adjustments.
7 min read
GLP-1s, Liver Health, and Digestive Innovations: A Medical Update
This comprehensive update delves into groundbreaking research on GLP-1 receptor agonists and their impact on liver health, alongside crucial developments in inflammatory bowel disease (IBD) management and innovative approaches to digestive symptom relief. Discover how cutting-edge science is shaping patient care and explore practical implications for managing chronic conditions.
7 min read
GLP-1 Medications: Understanding Drug Interactions and Safety
GLP-1 receptor agonists are powerful tools for managing diabetes and obesity, but understanding their potential interactions with other medications is crucial for patient safety and treatment efficacy.
7 min read
Oral Semaglutide Shows Promise for Pediatric Type 2 Diabetes
Novo Nordisk recently unveiled compelling topline results from the PIONEER TEENS trial, suggesting that oral semaglutide could become the first oral GLP-1 Receptor Agonist (RA) therapy approved for children and adolescents managing Type 2 Diabetes (T2D). This development addresses a significant gap in pediatric endocrinology, offering a potentially more accessible treatment option.
6 min read
Oral GLP-1 Drugs: A New Era for Weight Management in India
The landscape of weight management in India is on the cusp of a significant transformation with the advent of oral GLP-1 therapies. Driven by innovation from Chinese pharmaceutical companies and the impending patent expirations of existing treatments, these new pill-based options promise greater accessibility and affordability, fundamentally reshaping how obesity and metabolic disorders are addressed.
7 min read
What Happens to Your Body When You Take a GLP-1 Medication?
GLP-1 medications like Ozempic and Wegovy have transformed weight loss. But what exactly happens inside your body? We break down the science, mechanisms, and sustainability of peptide therapy.
8 min read
GLP-1 Drugs Show New Promise in Cardiovascular Procedures
New research suggests that GLP-1 receptor agonists, known for their roles in diabetes and weight management, may offer significant cardiovascular protection for patients undergoing complex procedures like TAVR and carotid artery stenting.
7 min read
Is Ozempic Killing Your Sex Drive? The Unexpected Side Effect of GLP-1 Drugs
A new study in Obesity Pillars suggests that while GLP-1 drugs aid weight loss, they may impact sexual desire through brain chemistry. Here is what you need to know.
2 min read
Indian Companies Rush to Make Generic GLP-1s Like Semaglutide
India's pharma giants are in a fierce race to develop generic GLP-1 drugs like semaglutide following its patent expiry, amid soaring obesity rates affecting nearly a third of adults. One executive dubbed it a 'bloodbath' as demand surges. Eli Lilly's CEO highlighted oral pills as a key solution to global supply shortages.
4 min read
Amazon, Walmart's GLP-1 Land Grab Bigger Than Weight Loss
Amazon and Walmart are racing to dominate GLP-1 medications like Eli Lilly's new oral Foundayo, but their strategies extend far beyond filling prescriptions for weight loss. With same-day delivery, telehealth, and integrated services, they're building 'continuous care commerce' platforms. This shift promises ongoing patient support for long-term therapy success.
5 min read
Study Finds Gastrointestinal Issues Top GLP-1 Side Effects
A comprehensive review of over 1,700 clinical trials reveals gastrointestinal adverse events as the most consistent side effects of GLP-1 medications like Ozempic and Wegovy. While these drugs show potential protective effects against infections and dementia, lawsuits over stomach paralysis and vision loss are mounting. Understand the findings and what they mean for your treatment.
5 min read
Jefferies Reiterates Buy on Eli Lilly Stock on GLP-1 Data
Jefferies has reiterated its Buy rating on Eli Lilly stock with a $1,300 price target, citing encouraging GLP-1 prescription data for the week ending March 13. Oral Wegovy showed strong performance in its 10th launch week, outpacing comparable injectables like Zepbound and Wegovy. Meanwhile, other GLP-1s saw slight declines amid Lilly's promising pipeline.
5 min read
Biomea Fusion Reports Positive Phase II Data for Diabetes Drug Icovamenib
Biomea Fusion has released promising Phase II data from the COVALENT-111 study, demonstrating icovamenib's ability to significantly reduce HbA1c levels in specific diabetes patient subgroups over 52 weeks. With no serious treatment-related adverse events and durable effects nine months post-dosing, this oral menin inhibitor could offer new options for metabolic disease management. Investors note positive stock momentum amid upcoming trials.
5 min read
GLP-1 RAs Linked to Lower Mortality in Brain Metastases, T2DM Patients
For patients battling cancer with brain metastases and type 2 diabetes, GLP-1 receptor agonists may offer a survival edge. A retrospective study of over 19,000 patients found GLP-1 RA users had significantly lower all-cause mortality (HR 0.63) after matching. This benefit held across major cancers and most GLP-1 RA types.
5 min read
20% of Eligible Youth Prescribed GLP-1 RAs, Study Finds
Just 20% of youth eligible for GLP-1 receptor agonists due to obesity are actually prescribed these medications, according to a recent Pediatrics study. Prescribing favors older adolescents with higher BMI and specific racial groups, but interruptions due to cost affect nearly two-thirds. This highlights gaps in access to promising obesity treatments for teens.
5 min read
GLP-1 Medications Like Ozempic May Cause Hair Loss: Here's Why
Social media is buzzing with reports of hair loss among GLP-1 users on drugs like Ozempic and Wegovy. While research is emerging, experts like Yale dermatologist Dr. Sara Perkins confirm patients are noticing more shedding. Here's the science behind it and steps to address it.
6 min read
Abbott Launches Extensior as Second Ozempic Brand in India
Abbott is now marketing Extensior, a second brand of Novo Nordisk's Ozempic, for type 2 diabetes management in India. This partnership comes as the semaglutide patent nears expiry, potentially lowering prices. With proven benefits in HbA1c control, weight loss, and cardiovascular risk reduction, it expands access in a country with over 100 million diabetes cases.
5 min read
Healthy Lifestyle Enhances GLP-1 Therapy's CV Benefits in Type 2 Diabetes
New research reveals that pairing GLP-1 receptor agonists with healthy lifestyle habits significantly lowers heart attack, stroke, and CV death risk in type 2 diabetes patients. Those following 6-8 habits plus GLP-1 therapy saw a 43% reduced MACE risk. This study highlights their complementary roles in heart health.
5 min read
GLP-1 RAs Reduce Food Noise by 46%, Emerging Evidence Shows
Emerging evidence suggests GLP-1 receptor agonists (GLP-1 RAs) not only aid weight loss but also significantly quiet 'food noise'—those persistent, distressing thoughts about food. In the US-based INFORM survey, 550 individuals using GLP-1s reported a 46% reduction in constant food thoughts, alongside mental health gains. This could redefine obesity management for better holistic outcomes.
6 min read
CoreAge Rx Named #1 GLP-1 Provider for 2026 by American Made GLP-1
American Made GLP-1 has crowned CoreAge Rx as the best GLP-1 provider for 2026, earning a stellar 4.9 out of 5 rating after reviewing over 10 U.S. telehealth platforms. The 'Editor's Choice' award highlights its FDA-approved semaglutide and tirzepatide programs with board-certified physician oversight. Patients report 10-26% body weight loss in 12 months with personalized care.
5 min read
Celebs Experiencing 'Ozempic Neck' from Rapid Weight Loss
Hollywood's shift to GLP-1 drugs like Ozempic has led to leaner figures on the red carpet, but some celebs are facing 'Ozempic neck'—loose skin from fast weight loss. This guide explains the phenomenon, its causes, and strategies to manage it. Understand why skin struggles to keep up with GLP-1-induced changes.
5 min read
GLP-1 Drugs & Hair Loss: New Study Reveals Potential Risk
Emerging research is spotlighting a potential link between popular GLP-1 medications like Ozempic and Wegovy and hair loss conditions such as telogen effluvium and androgenetic alopecia. A study of nearly 550,000 patients found a significant association after 12 months of use, even after adjusting for key factors. While benefits for diabetes and weight loss remain strong, awareness and monitoring are crucial.
6 min read
Oral Semaglutide Reduces Heart Failure Risk in Type 2 Diabetes: SOUL Trial
New analysis from the SOUL trial reveals oral semaglutide significantly reduces heart failure risks in type 2 diabetes patients who already have the condition. This benefit is especially notable in HFpEF cases, without compromising safety. Discover the details and implications for managing cardiometabolic disease.
5 min read
GLP-1 Risks for Seniors: Key Precautions for Older Adults
GLP-1 medications like Ozempic and Wegovy are transforming weight management, but older adults face heightened risks like muscle loss and fractures. This guide breaks down the science-backed concerns, monitoring strategies, and when to avoid them. Stay informed to make safer health choices.
4 min read
GLP-1 Kidney Risks: Study Compares Ozempic to SGLT2 Drugs
A recent Danish study in JAMA Internal Medicine highlights higher kidney risks with popular GLP-1 drugs like Ozempic compared to SGLT2 inhibitors. While GLP-1s offer weight loss benefits, understanding these findings is crucial for patients. Learn the science, risks, and how to protect your kidneys.
5 min read
GLP-1s and Muscle Loss: Evidence on Risks and Benefits
GLP-1 medications like semaglutide and tirzepatide deliver impressive weight loss, but fears of muscle wasting persist. Clinical evidence reveals these drugs cause modest, proportional lean mass changes while enhancing muscle quality. Discover the science and practical steps to optimize outcomes.
4 min read
Study: Biologics Safe with GLP-1 RAs? Insights from 250 Patients
A retrospective study of 250 adults found most safely used GLP-1 receptor agonists and dermatologic biologics together for 19 months. Only 19-39% of discontinuations linked to side effects, matching known individual drug profiles. Clinicians gain reassurance for patients with metabolic and immunologic needs.
2 min read
Cutaneous Reactions Rare Yet Differ Among GLP-1 Receptor Agonists
Research on FDA adverse event reports indicates that cutaneous side effects from GLP-1 receptor agonists occur infrequently, with variation depending on the drug. Semaglutide reported the highest rates, while dulaglutide had the lowest. Monitoring and awareness are key for patients using these medications.
3 min read
Australia Issues Mental Health Alert for Weight-Loss Medications Like Ozempic
The Therapeutic Goods Administration (TGA) has issued new safety alerts concerning weight loss and diabetes medications. These warnings address potential mental health risks and reduced effectiveness of oral contraceptives when using drugs like Mounjaro.
2 min read
Why Indians Should Use Ozempic Cautiously: Understanding the Reason
With the introduction of new weight-loss and diabetes drugs like Ozempic in India, endocrinologists are emphasizing the need for cautious and medically supervised use. Concerns arise particularly for individuals with a 'thin-fat' phenotype, who may experience adverse effects.
3 min read
Ozempic-like Medications: New Alert Issued Over Suicidal Thought Risk
Australia's Therapeutic Goods Administration (TGA) has issued a safety alert concerning Ozempic-style drugs and a potential connection to suicidal thoughts and behaviors. While a direct causal link hasn't been established, the TGA advises patients to immediately inform their healthcare provider if they experience any changes in mood or behavior.
4 min read
Ozempic's Impact: Reshaping Supermarkets and Stock Valuations
The rise in popularity of weight loss medications such as Ozempic and Mounjaro is significantly impacting both the food industry and the stock market. Eli Lilly, a pharmaceutical company, experienced a surge in valuation after reporting substantial sales increases. These drugs are changing eating patterns and redefining obesity treatment.
6 min read
Are Sexual Adverse Reactions Emerging With GLP-1 Receptor Agonists?
GLP-1 agonists, initially for blood sugar and weight loss, are now investigated for their impact on sexual function. Studies reveal diverse effects on libido, influenced by various factors. Some experience increased libido, while others report a decline.
4 min read